This week, Novo Nordisk’s Bio Innovation Hub in Boston/Cambridge, in collaboration with Portal Innovations, just launched the 2024 Pathbreakers Program, offering partnering and investment opportunities for U.S.-based biotech startups.
Novo Nordisk’s Bio Innovation Hub is most interested in co-creation opportunities with startups that are developing platform technologies with disease agnostic potential or are interested in exploring scientific projects within the cardiometabolic space. Biotechs that have not previously worked within cardiometabolic diseases but are interested in exploring new indications for their technology or platform are encouraged to apply.
Applicants are invited to submit their proposal to one of three categories:
- A Portal Innovations ecosystem placement
- A Portal Innovations venture capital investment
- A partnership with Novo Nordisk
The deadline for applications is January 24th, 2024 by 11:59 pm ET and you can find the application and further submission instructions at this link here.
